Global Psoriasis Therapeutics Market 2015-2019

乾癬及び乾癬性関節炎治療薬の世界市場

◆タイトル:Global Psoriasis Therapeutics Market 2015-2019
◆商品コード:IRTNTR4943
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年12月31日
◆ページ数:109
◆資料形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥372,900見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、乾癬及び乾癬性関節炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、乾癬及び乾癬性関節炎治療薬の世界市場規模及び予測、種類別分析、作用機序別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Psoriasis and Its Types
Psoriasis is a common immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes buildup of thick white, red, or silvery patches of skin. It alters the normal cell cycle of the skin. The new cells of the skin grow and move quickly to the surface of the skin to form patches known as “plaques”. The plaques are commonly found on knees, elbows, scalp, hands, and feet. Psoriasis occurs mostly in adults, but can also be seen in children and adolescents. The etiology of the disease is unknown, however, it is believed to be an immune-mediated process. It is believed that the over-activity of the immune system can cause inflammation, thereby resulting in flaking of the skin.

TechNavio’s analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 9.95 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Psoriasis Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs including systemic and topical drugs used in the treatment of:
• Psoriasis
• Psoriatic Arthritis

The Global Psoriasis Therapeutics market is segmented based on the mechanism of action of the drugs used to treat psoriasis and psoriatic arthritis as illustrated below:
• TNF Inhibitors
• PDE4 Inhibitors
• Interleukin Blockers
• Others

The Global Psoriasis Therapeutics market is also segmented based on the type of molecule used for the treatment of psoriasis, as illustrated below:
• Biologics
• Small Molecules

On the basis of route of administration adopted for the treatment of psoriasis, the Global Psoriasis Therapeutics market is segmented as follows:
• Oral
• Parenteral
• Topical

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Psoriasis Therapeutics market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of psoriasis have been discussed.

TechNavio’s report, Global Psoriasis Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and the EMEA regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Abbvie
• Amgen
• Janssen Pharmaceuticals
• Pfizer

[Other Prominent Vendors]
• AbGenomics
• Almirall
• Anacor Pharmaceuticals
• ApoPharma
• Astellas Pharma
• AstraZeneca
• Aurinia Pharmaceuticals
• Biocon
• Biogen Idec
• Biotest
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Can-Fite BioPharma
• Celgene
• Coherus Biosciences
• Creabilis
• Dermira
• Eli Lilly
• F. Hofffmann-La Roche
• Forward Pharma
• G & W Laboratories
• GlaxoSmithKline
• Idera Pharmaceuticals
• Kadmon
• Kyowa Hakko Kirin
• LEO Pharma
• Maruho
• Merck
• Moleculin
• MorphoSys
• Novartis
• Pfizer
• Promius Pharma
• Provectus Biopharmaceuticals
• Sandoz
• Sun Pharmaceuticals
• Takeda Pharmaceutical
• Taro Pharmaceuticals
• Therapeutics Inc.
• UCB
• Valeant Pharmaceuticals
• VBL Therapeutics

[Market Driver]
• Growing Unmet Needs
• For a full, detailed list, view our report

[Market Challenge]
• Unknown Disease Etiology
• For a full, detailed list, view our report

[Market Trend]
• Market Dominance by Biologics
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Humira
04.1.2 Enbrel
04.1.3 Otezla
04.1.4 Remicade
04.1.5 Stelara

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Mechanism of Action
08.1 TNF Inhibitors
08.2 PDE4 Inhibitors
08.3 Interleukin Blockers
08.4 Others

09.Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Small Molecules

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
10.3 Topical

11.Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
11.3 Semi-solid

12.Market Segmentation by Type of Disease
12.1 Mild Psoriasis
12.2 Moderate Psoriasis
12.3 Severe Psoriasis

13.Geographical Segmentation

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Pipeline Portfolio

22.Novel Mechanisms Targeted by Pipeline Candidates
22.1 Small Molecules
22.1.1 Tofacitinib
22.1.2 Baricitinib
22.2 Biologics
22.2.1 Ixekizumab
22.2.2 Secukinumab
22.2.3 Brodalumab
22.2.4 Tildrakizumab
22.2.5 Guselkumab

23.Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2014
23.2.1 Competitive Assessment of Top Drugs for Psoriasis
23.2.2 Abbvie
23.2.3 Janssen Pharmaceuticals
23.2.4 Amgen
23.2.5 Pfizer
23.3 Other and Future Prominent Vendors

24.Key Vendor Analysis
20.1 Abbvie
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Revenue by Business Segmentation
20.1.5 Revenue Comparison 2013 and 2014
20.1.6 Sales by Geography
22.1.7 Business Strategy
22.1.8 Key Developments
22.1.9 SWOT Analysis
20.2 Amgen
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Segmentation
20.2.4 Revenue by Business Segmentation
20.2.5 Revenue Comparison 2013 and 2014
20.2.6 Sales by Geography
20.2.7 Business Strategy
20.2.8 Key Developments
20.2.9 SWOT Analysis
20.3 Janssen Pharmaceuticals
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2013 and 2014
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Pfizer
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2013 and 2014
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis

25.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of the Global Psoriasis Therapeutics Market
Exhibit 3: Global Psoriasis Therapeutics Market 2014-2019 (US$ million)
Exhibit 4: Drivers and Challenges of Global Psoriasis Therapeutics Market
Exhibit 5: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action
Exhibit 6: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action 2014
Exhibit 7: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule
Exhibit 8: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule 2014
Exhibit 9: Global Psoriasis Therapeutics Market Segmentation by Route of Administration
Exhibit 10: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 11: Global Psoriasis Therapeutics Market Segmentation by Dosage Form
Exhibit 12: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 13: Global Psoriasis Therapeutics Market Segmentation by Type of Disease
Exhibit 14: Global Psoriasis Therapeutics Market Segmentation by Type of Disease 2014
Exhibit 15: Global Psoriasis Therapeutics Market by Geographical Segmentation 2014
Exhibit 16: Buying Criteria of the Global Psoriasis Therapeutics Market
Exhibit 17: Drivers and Their Impact on the Key Customer Category of the Global Psoriasis Therapeutics Market
Exhibit 18: Drivers and Their Geography-wise Impact on the Global Psoriasis Therapeutics Market
Exhibit 19: Phase III Pipeline Molecules for Psoriasis
Exhibit 20: Percentage Comparison of Pipeline Molecules for Psoriasis Treatment
Exhibit 21: Novel Targets of the Pipeline Candidates
Exhibit 22: Candidates Under Development: Tofacitinib
Exhibit 23: Candidates Under Development: Baricitinib
Exhibit 24: Candidates Under Development: Ixekizumab
Exhibit 25: Candidates Under Development: Sekukinumab
Exhibit 26: Candidates Under Development: Brodalumab
Exhibit 27: Candidates Under Development: Tildrakizumab
Exhibit 28: Candidates Under Development: Guselkumab
Exhibit 29: YoY Sales Comparison of Top Drugs for Psoriasis 2010-2013 (US$ million)
Exhibit 30: Revenue Share of the Top Drugs for Psoriasis 2011-2013
Exhibit 31: YoY Global Sales of Humira 2008-2013
Exhibit 32: YoY Global Sales of Remicade 2005-2013
Exhibit 33: YoY Global Sales of Stelara 2005-2013
Exhibit 34: YoY Sales of Enbrel (In US and Canada) 2005-2013
Exhibit 35: YoY Sales of Enbrel In US 2005-2013
Exhibit 36: YoY Sales of Enbrel In Canada 2005-2013
Exhibit 37: Region-wise Sales Comparison of Enbrel 2005-2013
Exhibit 38: YoY Sales of Enbrel (Outside US and Canada) 2009-2013
Exhibit 39: Abbvie: Business Segmentation 2014
Exhibit 40: Abbvie: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 41: Abbvie: Sales by Geography (in US$ million)
Exhibit 42: Amgen: Business Segmentation by Revenue 2013 and 2014
Exhibit 43: Amgen: Sales by Geography 2014 (Pharmaceuticals Division)
Exhibit 44: Amgen: Sales by Geography 2014 (Diagnostics Division)
Exhibit 45: Janssen: Business Segmentation by Revenue 2014
Exhibit 46: Janssen: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 47: Janssen: Sales by Geography 2014
Exhibit 48: Pfizer: Business Segmentation
Exhibit 49: Pfizer: Revenue by Business Segmentation 2014
Exhibit 50: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
Exhibit 51: Pfizer: Revenue by Geographical Segmentation 2014



【掲載企業】

Abbvie,Amgen,Janssen Pharmaceuticals ,Pfizer,AbGenomics,Almirall ,Anacor Pharmaceuticals,ApoPharma,Astellas Pharma,AstraZeneca,Aurinia Pharmaceuticals,Biocon,Biogen Idec,Biotest ,Boehringer Ingelheim,Bristol-Myers Squibb,Can-Fite BioPharma,Celgene,CoherusBiosciences,Creabilis,Dermira,Eli Lilly,F. Hofffmann-La Roche,Forward Pharma,G & W Laboratories,GlaxoSmithKline,Idera Pharmaceuticals,Kadmon ,Kyowa Hakko Kirin,LEO Pharma,Maruho,Merck,Moleculin,MorphoSys,Novartis,Pfizer,Promius Pharma,Provectus Biopharmaceuticals,Sandoz,Sun Pharmaceuticals,Takeda Pharmaceutical,Taro Pharmaceuticals,Therapeutics Inc. ,UCB,Valeant Pharmaceuticals,VBL Therapeutics

【資料のキーワード】

乾癬、乾癬性関節炎、治療薬、医薬品、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[乾癬及び乾癬性関節炎治療薬の世界市場] (Global Psoriasis Therapeutics Market 2015-2019 / IRTNTR4943)販売に関する免責事項
[乾癬及び乾癬性関節炎治療薬の世界市場] (Global Psoriasis Therapeutics Market 2015-2019 / IRTNTR4943)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆